Myriad Genetics Folate Receptor Alpha Biomarker

Myriad Genetics said that it has added folate receptor alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds a companion diagnostic option for healthcare providers to help guide treatment decisions for patients with ovarian cancer. FRα establishes patient eligibility for Immunogen's Elahere(mirvetuximab soravtansine-gynx), the only US Food and Drug Administration-approved drug for patients who are FRα-positive and resistant to platinum-based chemotherapy. FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer, Myriad noted. The new biomarker can be ordered from Myriad alongside other companion diagnostic tests, and oncologists can also choose to receive germline, HRD, FRα biomarker, and tumor testing results from a single laboratory.